3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
3
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Fibroadenoma
1
Colorectal Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Breast Diseases
1
Interventions
Fluorodeoxyglucose F18
3
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
tivozanib
1
romidepsin
1
pembrolizumab
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
atezolizumab
1
alectinib
1
aldesleukin
1
Specimen Handling
1
Quality of Life
1
Patient Reported Outcome Measures
1
Nivolumab
1
Neuropsychological Tests
1
Molecular Diagnostic Techniques
1
Lactones
1
Interleukin-13
1
Immunotherapy
1
FAPI-46
1
Drug Therapy
1
Depsipeptides
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
gadoterate meglumine
×
Breast
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled